BioMimetic Therapeutics, Inc. (BMTI) Receives Filing Letter from FDA for Augment(TM) Bone Graft PMA  
6/29/2010 8:11:12 AM

FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augmentâ„¢ Bone Graft for use in foot and ankle fusions in the U.S. The FDA has now filed the application and begun the comprehensive review of the clinical module.